<DOC>
	<DOCNO>NCT02951429</DOCNO>
	<brief_summary>This Phase IIb , randomize , placebo-controlled , multicenter , international study evaluate efficacy , safety , tolerability sildenafil placebo add pirfenidone ( Esbriet ) treatment participant advance IPF intermediate high probability Group 3 pulmonary hypertension ( PH ) stable dose pirfenidone demonstrate tolerability . Participants randomize receive 1 year treatment either oral sildenafil match placebo continue take pirfenidone .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Study Pirfenidone Combination With Sildenafil Participants With Advanced Idiopathic Pulmonary Fibrosis ( IPF ) Intermediate High Probability Group 3 Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Diagnosis IPF least 3 month prior Screening Confirmation IPF diagnosis investigator accordance 2011 international consensus guideline screen Advanced IPF ( define measurable carbon monoxide diffuse capacity [ DLCO ] less equal ( &lt; = ) 40 % predict value Screening ) intermediate high probability group 3 pulmonary hypertension ( PH ) Participants receive pirfenidone least 12 week , dose range 1602 2403 mg/day least 4 week prior Screening must experience either new ongoing adverse event National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) ( version 4.03 ) Grade 2 high consider investigator related pirfenidone , interruption pirfenidone treatment great ( &gt; ) 7 day reason WHO Functional Class II III Screening 6MWD 100 450 meter screen Women childbearing potential men surgically sterile agreement remain abstinent use contraceptive measure History follow type PH : Group 1 ( PAH ) ; Group 1 ( pulmonary venoocclusive disease and/or pulmonary capillary hemangiomatosis ) ; Group 2 ( leftheart disease ) ; Group 3 ( due condition interstitial lung disease , include chronic obstructive pulmonary disease [ COPD ] , sleepdisordered breathing , alveolar hypoventilation , high altitude , developmental abnormality ) ; Group 4 ( chronic thromboembolic pulmonary hypertension ) ; Group 5 ( disorder ) History clinically significant cardiac disease History coexistent clinically significant COPD , bronchiectasis , asthma , inadequately treat sleepdisordered breathing , clinically significant pulmonary disease disorder IPF PH secondary IPF History use drug toxin know cause PAH , include aminorex , fenfluramine , dexenfluramine , amphetamine FEV1/FVC ratio le ( &lt; ) 0.70 post bronchodilator ; SpO2 saturation rest &lt; 92 % &gt; = 6 liter ( L ) supplemental oxygen Screening Extent emphysema great extent fibrotic change ( honeycomb reticular change ) previous highresolution compute tomography ( HRCT ) scan , opinion Investigator Smoked tobacco within 3 month prior screen unwilling avoid tobacco product ( cigarette , pipe , cigar ) throughout study Illicit drug significant alcohol abuse Electrocardiogram ( ECG ) heartrate correct QT interval ( correct use Fridericia 's formula [ QTcF ] ) &gt; =500 millisecond ( m ) screening , family personal history long QT syndrome Exclusion criterion base pirfenidone reference safety information : 1. participant history angioedema due pirfenidone ; 2. concomitant use fluvoxamine Exclusion criterion base sildenafil reference safety information : 1. coadministration nitric oxide donor organic nitrate , phosphodiesterase5 ( PDE5 ) inhibitor , guanylate cyclase stimulators , potent Cytochrome P450 3A4 ( CYP3A4 ) inhibitor ; 2. loss vision one eye nonarteritic anterior ischemic optic neuropathy ( NAION ) ; 3. use alphablocker ; 4. participant bleed disorder active peptic ulceration ; 5. know hereditary degenerative retinal disorder retinitis pigmentosa ; 6. galactose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>